Trilostane

  • #LGM Pharma is a Trilostane CAS# 13647-35-3 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 13647-35-3
  • AHFC code:
  • Synonyms:
  • ATC Code: H02CA01
  • Chemical Formula: C14H18N4O3
  • Molecular Weight: 329.4333
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB01108 (APRD01276)
  • SMILES: C[C,]12CC[C,H]3[C,,H](CC[C,,]45O[C,,H]4C(O)=C(C[C,]35C)C#N)[C,,H]1CC[C,,H]2O
  • InChl: KVJXBPDAXMEYOA-CXANFOAXSA-N
  • PubChem:
  • IUPAC: (1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile

Additional Details

Indication:
Used in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.
Pharmacodynamics:
Trilostane blocks an enzyme involved in the production of several steroids including cortisol. Inhibiting this enzyme inhibits the production of cortisol. In Cushing's syndrome, the adrenal gland overproduces steroids. Although steroids are important for various functions of the body, too much can cause problems. Trilostane reduces the amount of steroids produced by the adrenal gland. This product was withdrawn from the U.S. market in April 1994.
Mode of Action:
Trilostane produces suppression of the adrenal cortex by inhibiting enzymatic conversion of steroids by 3-beta-hydroxysteroid dehydrogenase/delta 5,4 ketosteroid isomerase, thus blocking synthesis of adrenal steroids.
Metabolism:
Hepatic.
Toxicity:
Symptoms of overdose include darkening of skin, drowsiness or tiredness, loss of appetite, mental depression, skin rash, and/or vomiting.
General Reference:
Komanicky P, Spark RF, Melby JC: Treatment of Cushingês syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab. 1978 Nov;47(5):1042-51. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos